TitleDeficiency of CCAAT/enhancer binding protein-epsilon reduces atherosclerotic lesions in LDLR-/- mice.
Publication TypeJournal Article
Year of Publication2014
AuthorsOkamoto R, Gery S, Gombart AF, Wang X, Castellani LW, Akagi T, Chen S, Arditi M, Ho Q, Lusis AJ, Li Q, H Koeffler P
JournalPLoS One
Volume9
Issue1
Paginatione85341
Date Published2014
ISSN1932-6203
KeywordsAnimals, Atherosclerosis, CCAAT-Enhancer-Binding Proteins, Cell Movement, Immunohistochemistry, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Receptors, LDL
Abstract

The CCAAT/enhancer binding proteins (C/EBPs) are transcription factors involved in hematopoietic cell development and induction of several inflammatory mediators. C/EBPε is expressed only in myeloid cells including monocytes/macrophages. Atherosclerosis is an inflammatory disorder of the vascular wall and circulating immune cells such as monocytes/macrophages. Mice deficient in the low density lipoprotein (LDL) receptor (Ldlr-/-) fed on a high cholesterol diet (HCD) show elevated blood cholesterol levels and are widely used as models to study human atherosclerosis. In this study, we generated Ldlr and Cebpe double-knockout (llee) mice and compared their atherogenic phenotypes to Ldlr single deficient (llEE) mice after HCD. Macrophages from llee mice have reduced lipid uptake by foam cells and impaired phagokinetic motility in vitro compared to macrophages from llEE mice. Also, compared to llEE mice, llee mice have alterations of lipid metabolism, and reduced atheroma and obesity, particularly the males. Peritoneal macrophages of llee male mice have reduced mRNA expression of FABP4, a fatty acid binding protein implicated in atherosclerosis. Overall, our study suggests that the myeloid specific factor C/EBPε is involved in systemic lipid metabolism and that silencing of C/EBPε could decrease the development of atherosclerosis.

DOI10.1371/journal.pone.0085341
Alternate JournalPLoS ONE
PubMed ID24489659
PubMed Central IDPMC3904867
Grant ListR01 HL066436 / HL / NHLBI NIH HHS / United States
2R01 CA026038-32 / CA / NCI NIH HHS / United States
5R01AI65604-6 / AI / NIAID NIH HHS / United States